Business Wire

W-INITIATIVE

1.6.2022 13:27:08 CEST | Business Wire | Press release

Share
Casper Ruud Appointed Global Ambassador for W Initiative

Norway’s best tennis player and superstar Casper Ruud (23) is the new global ambassador for the Norwegian humanitarian foundation W Initiative. The agreement involves a close partnership over the next three years.

W Initiative was established in 2021 by SalMar heir Gustav Magnar Witzoe (29), to support humanitarian activities that improve the quality of life for children and young people around the world.

“I am proud to promote W Initiative on an international arena. I can think of nothing more meaningful than to help children and young people have a better live, better health and more equal opportunities, which also includes games and sports,” says Casper Ruud, who is currently competing in the French Open Grand Slam tournament.

Long-term partnership
As ambassador, Casper Ruud will be promoting the foundation and making it more visible to an international audience. This includes wearing the W Initiative logo on his clothing, talking about the foundation’s work during interviews, in social media and on his own website, as well as participating in various events organised by the foundation. The goal for the W Initiative is to be more visible and, consequently, receive information about and access to new projects around the world that it can support.

“The foundation actively searches for projects around the world that align with key sustainability goals. Having Casper Ruud as an ambassador will open more doors and we can reach international audiences in a completely different way,” explains Managing Director of the foundation Eirik Boe Sletten.

Gustav Magnar Witzoe created W Initiative in 2021 and it is Witzoe’s company Forward Project that is funding the partnership with Casper Ruud, which starts on 1 June and lasts until the end of 2024. W Initiative will then have the preferential right to extend the partnership for another two years.

The right man
“When I first met Casper, it was immediately clear that he was the right ambassador for the foundation – not only because he is one of the world’s best athletes who plays on the world’s premiere arenas, but also because he is simply a great guy who shares the foundation’s values and views. His contribution comes at an important time in the evolution of the foundation. If this partnership can also contribute positively to his own development as Norway’s best tennis player, that’s fantastic,” says Witzoe.

Witzoe comes from a small rural Island off the west coast of Norway with a population of just over 4000. His father pioneered the fish farming industry, in time becoming one of the world’s most successful in the industry, with his company SalMar.

W Initiative aims to grow through effective management and expansion to make increasingly meaningful contributions.

“Our first project in Uganda, which is being carried out together with Right To Play, contributes to better water and sanitary conditions, in addition to games and sports for children in three districts in the country. We have also joined a new project in Fiji headed by FijiStiftelsen. Thanks to the support of the W Initiative, FijiStiftelsen will be building two evacuation centres that will be used daily as a classroom and multipurpose room for children, as well as give women the opportunity to create their own workplace,” explains Boe Sletten.

Download pictures here: Pictures

More info here: https://www.w-initiative.com/en

W Initiative facts and figures

W Initiative is a newly established humanitarian foundation that aims to improve the quality of life of children and young people. The projects supported by the foundation may be in Norway or elsewhere but must always be grounded in UN Sustainable Development Goals 3, 4, 5, 6 or 10. The projects must have a focus on increased competence, better health, and more equal opportunities. Gustav Magnar Witzoe has donated NOK 110 million to the foundation through his family-owned company, of which NOK 100 million is earmarked for the foundation’s founding capital to enable increasingly meaningful contributions through effective management and expansion. The foundation will actively seek out projects that align with its vision and purpose and it will not be possible to apply for funding from the foundation. The foundation wishes to work together with well-established organisations. An annual report will be published on status and progress based on the foundation’s objectives.

Management board

Witzoe is the son of SalMar founder Gustav Witzoe and is currently the majority shareholder of the parent company Kvarv AS. The management board also includes NTNU professor Heri Ramampiaro, associate attorney Kristina Jorgensen, chief physician Elisabeth Vesterbekkmo and civil engineer Magnus Witzoe. All board members have a different background, but with a strong affiliation with Trondelag.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye